The Norwegian Immunotherapy in Multiple Myeloma Study

Recruiting Observational Study
Myeloma Multiple Plasma Cell Leukemia AL Amyloidosis
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
400 (estimated)
Sponsor
St. Olavs Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we ca…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria * Participants age ≥ 18 years * Prior diagnosis of one of the following * Multiple myeloma as defined according to IMWG criteria * Primary plasma cell leukemia as defined according to IMWG consensus definition * AL-amyloidosis as defined according to IMWG criteria * Planne…
Contacts

Tobias S Slørdahl, MD PhD

+4772825100

tobias.s.slordahl@ntnu.no

CONTACT

Juni S Paulsen, MD

+4772825100

juni.paulsen@ntnu.no

CONTACT